Alpha Cognition is a clinical stage, biopharmaceutical company dedicated to developing novel treatments for under-served neurodegenerative diseases such as Alzheimer’s Dementia and Amyotrophic Lateral Sclerosis (ALS). ALPHA-1062, a patented new chemical entity that has demonstrated safety and improved tolerability in human clinical trials. It is being developed as a new acetylcholine esterase inhibitor for the treatment of dementia of the Alzheimer’s type, with minimal gastrointestinal side-effects and novel routes of administration. ALPHA-0602 is a gene therapy program delivering progranulin, a neurotrophic protein. It is in preclinical development for the treatment of ALS. ALPHA-0602 is patented and has received Orphan Drug Designation from the FDA.
Looking for a particular Alpha Cognition, Inc. employee's phone or email?
Alpha Cognition, Inc. Questions
The Alpha Cognition, Inc. annual revenue was $13.2 million in 2026.
Denis Kay is the Co-Founder and Chief Scientific Officer at Alpha Cognition Inc. of Alpha Cognition, Inc..
74 people are employed at Alpha Cognition, Inc..
Alpha Cognition, Inc. is based in Vancouver, British Columbia.
The NAICS codes for Alpha Cognition, Inc. are [325, 3254, 32, 32541].
The SIC codes for Alpha Cognition, Inc. are [283, 28].
Top Alpha Cognition, Inc. Employees
-
24 -
Michael McFadden
Chief Executive Officer at Alpha Cognition, Inc.
Texas, United States35+ -
Robert Wills
Chairman of the Board at Alpha Cognition at Alpha Cognition, Inc.
Spring Lake, NJ, US14 -
Lauren D'Angelo
Chief Operating Officer at Alpha Cognition, Inc.
Texas, United States25 -
Michael Spence
Area Vice President, LTC Sales - West at Alpha Cognition, Inc.
Texas, United States35+ -
35 -
Kurt Grady
Vice President Medical Affairs at Alpha Cognition, Inc.
St. Louis, MO, US32 -
Jennifer Pesa
Vice President, Commercial at Alpha Cognition, Inc.
Fort Wayne, IN, US23 -
Andrew Wahlert
Director, Medical Affairs at Alpha Cognition, Inc.
California, United States24
Related Companies
